Id: acc1786
Group: 2sens
Protein: eIF2alpha
Gene Symbol: EIF2A
Protein Id: Q9BY44
Protein Name: EIF2A_HUMAN
PTM: phosphorylation
Site: Ser51
Site Sequence: CIFSKDGTLFAWGNGEKVNII
Disease Category: Cancer
Disease: Breast Cancer
Disease Subtype:
Disease Cellline: MDA-MB-231
Disease Info:
Drug: rapalogues
Drug Info: -
Effect: increase
Effect Info: "Hyperphosphorylation of eIF2alpha reduces the survival rate of cancer cells, enhances the cytotoxic effects of established antitumor therapies, and circumvents resistance to rapalogues."
Note:
Score: 5.0
Pubmed(PMID): 24204783
Sentence Index:
Sentence:

Sequence & Structure:

MAPSTPLLTVRGSEGLYMVNGPPHFTESTVFPRESGKNCKVCIFSKDGTLFAWGNGEKVNIISVTNKGLLHSFDLLKAVCLEFSPKNTVLATWQPYTTSKDGTAGIPNLQLYDVKTGTCLKSFIQKKMQNWCPSWSEDETLCARNVNNEVHFFENNNFNTIANKLHLQKINDFVLSPGPQPYKVAVYVPGSKGAPSFVRLYQYPNFAGPHAALANKSFFKADKVTMLWNKKATAVLVIASTDVDKTGASYYGEQTLHYIATNGESAVVQLPKNGPIYDVVWNSSSTEFCAVYGFMPAKATIFNLKCDPVFDFGTGPRNAAYYSPHGHILVLAGFGNLRGQMEVWDVKNYKLISKPVASDSTYFAWCPDGEHILTATCAPRLRVNNGYKIWHYTGSILHKYDVPSNAELWQVSWQPFLDGIFPAKTITYQAVPSEVPNEEPKVATAYRPPALRNKPITNSKLHEEEPPQNMKPQSGNDKPLSKTALKNQRKHEAKKAAKQEARSDKSPDLAPTPAPQSTPRNTVSQSISGDPEIDKKIKNLKKKLKAIEQLKEQAATGKQLEKNQLEKIQKETALLQELEDLELGI

Select PDB:

Known Drugs:

source: Multi-Sources

(see table)

No data.

Protein Tractability:

source: Open Targets
Small molecule
Antibody
PROTAC
Other modalities
Approved Drug
Advanced Clinical
Phase 1 Clinical
Structure with Ligand
High-Quality Ligand
High-Quality Pocket
Med-Quality Pocket
Druggable Family
Approved Drug
Advanced Clinical
Phase 1 Clinical
UniProt loc high conf
GO CC high conf
UniProt loc med conf
UniProt SigP or TMHMM
GO CC med conf
Human Protein Atlas loc
Approved Drug
Advanced Clinical
Phase 1 Clinical
Literature
UniProt Ubiquitination
Database Ubiquitination
Half-life Data
Small Molecule Binder
Approved Drug
Advanced Clinical
Phase 1 Clinical

PTM Intensity:

source: CPTAC

No intensity data of this site,
show all other sites!

EIF2A-Ser481
Cancer Intensity
BRCA 0.254
COAD -1.143
HGSC 1.978
ccRCC 0.421
GBM -0.483
HNSC 0.059
LUAD -1.003
LUSC -1.463
non_ccRCC 1.047
PDAC 0.224
UCEC 0.108
EIF2A-Ser501
Cancer Intensity
BRCA 0.096
COAD 0.065
HGSC 2.656
ccRCC -0.628
GBM -0.4
HNSC -0.228
LUAD -0.676
LUSC
non_ccRCC -0.5
PDAC 0.33
UCEC -0.715
EIF2A-Ser503
Cancer Intensity
BRCA
COAD -1.132
HGSC 1.288
ccRCC -0.657
GBM
HNSC
LUAD
LUSC -0.842
non_ccRCC
PDAC 0.76
UCEC 0.584
EIF2A-Thr487
Cancer Intensity
BRCA
COAD -0.905
HGSC -0.168
ccRCC
GBM
HNSC
LUAD
LUSC
non_ccRCC
PDAC
UCEC 1.073
EIF2AK1-Ser257
Cancer Intensity
BRCA
COAD
HGSC
ccRCC
GBM -0.294
HNSC 1.036
LUAD -0.623
LUSC -1.165
non_ccRCC
PDAC
UCEC 1.046
EIF2AK1-Ser294
Cancer Intensity
BRCA
COAD
HGSC
ccRCC
GBM 1.069
HNSC -0.751
LUAD
LUSC -0.948
non_ccRCC
PDAC
UCEC 0.629
EIF2AK2-Ser167
Cancer Intensity
BRCA
COAD
HGSC
ccRCC
GBM
HNSC 0.707
LUAD -0.707
LUSC
non_ccRCC
PDAC
UCEC
EIF2AK2-Ser171
Cancer Intensity
BRCA
COAD
HGSC
ccRCC
GBM
HNSC -0.707
LUAD
LUSC
non_ccRCC
PDAC
UCEC 0.707
EIF2AK2-Ser33
Cancer Intensity
BRCA
COAD
HGSC -0.707
ccRCC
GBM
HNSC
LUAD
LUSC 0.707
non_ccRCC
PDAC
UCEC
EIF2AK2-Ser83
Cancer Intensity
BRCA -0.012
COAD -0.018
HGSC -0.58
ccRCC
GBM 1.525
HNSC -1.437
LUAD
LUSC 0.522
non_ccRCC
PDAC
UCEC
EIF2AK2-Ser92
Cancer Intensity
BRCA
COAD
HGSC -1.155
ccRCC 0.586
GBM
HNSC
LUAD 0.569
LUSC
non_ccRCC
PDAC
UCEC
EIF2AK2-Ser93
Cancer Intensity
BRCA
COAD 0.953
HGSC -1.041
ccRCC
GBM
HNSC 0.088
LUAD
LUSC
non_ccRCC
PDAC
UCEC
EIF2AK2-Thr170
Cancer Intensity
BRCA
COAD
HGSC
ccRCC
GBM
HNSC 0.707
LUAD -0.707
LUSC
non_ccRCC
PDAC
UCEC
EIF2AK3-Ser404
Cancer Intensity
BRCA -1.974
COAD
HGSC 1.579
ccRCC 0.387
GBM 0.07
HNSC 0.184
LUAD 0.272
LUSC -0.245
non_ccRCC 0.654
PDAC -0.928
UCEC
EIF2AK3-Ser537
Cancer Intensity
BRCA -0.088
COAD
HGSC
ccRCC
GBM
HNSC
LUAD 1.35
LUSC -1.063
non_ccRCC
PDAC -0.199
UCEC
EIF2AK3-Ser564
Cancer Intensity
BRCA -0.021
COAD -1.697
HGSC 2.192
ccRCC -0.232
GBM -0.048
HNSC -0.516
LUAD 0.425
LUSC 0.147
non_ccRCC 0.49
PDAC -0.74
UCEC
EIF2AK3-Ser660
Cancer Intensity
BRCA -1.439
COAD
HGSC
ccRCC 0.68
GBM 0.12
HNSC
LUAD 1.11
LUSC -0.471
non_ccRCC
PDAC
UCEC
EIF2AK3-Ser705
Cancer Intensity
BRCA
COAD
HGSC
ccRCC 0.707
GBM
HNSC -0.707
LUAD
LUSC
non_ccRCC
PDAC
UCEC
EIF2AK3-Ser941
Cancer Intensity
BRCA 0.741
COAD
HGSC
ccRCC -1.96
GBM 0.242
HNSC 0.29
LUAD
LUSC 0.684
non_ccRCC
PDAC 0.004
UCEC
EIF2AK3-Ser943
Cancer Intensity
BRCA -1.617
COAD
HGSC 2.07
ccRCC 0.226
GBM -0.082
HNSC -0.331
LUAD -0.373
LUSC -0.018
non_ccRCC 0.69
PDAC -0.564
UCEC
EIF2AK3-Ser945
Cancer Intensity
BRCA
COAD
HGSC
ccRCC
GBM 0.953
HNSC
LUAD -1.041
LUSC
non_ccRCC
PDAC 0.089
UCEC
EIF2AK3-Ser964
Cancer Intensity
BRCA
COAD -0.707
HGSC 0.707
ccRCC
GBM
HNSC
LUAD
LUSC
non_ccRCC
PDAC
UCEC
EIF2AK3-Thr406
Cancer Intensity
BRCA
COAD 0.694
HGSC
ccRCC
GBM
HNSC -1.146
LUAD
LUSC 0.452
non_ccRCC
PDAC
UCEC
EIF2AK4-Ser230
Cancer Intensity
BRCA -0.445
COAD
HGSC 2.732
ccRCC -0.395
GBM -0.115
HNSC -0.278
LUAD -0.804
LUSC -0.508
non_ccRCC 0.268
PDAC -0.152
UCEC -0.303
EIF2AK4-Ser572
Cancer Intensity
BRCA
COAD
HGSC
ccRCC
GBM
HNSC 0.78
LUAD
LUSC -1.127
non_ccRCC
PDAC
UCEC 0.348
EIF2AK4-Ser770
Cancer Intensity
BRCA
COAD
HGSC
ccRCC
GBM -0.14
HNSC -0.893
LUAD -0.187
LUSC -0.528
non_ccRCC 2.1
PDAC -0.621
UCEC 0.269
EIF2AK4-Thr667
Cancer Intensity
BRCA -0.718
COAD -0.434
HGSC 2.669
ccRCC -0.092
GBM 0.155
HNSC -0.464
LUAD -0.237
LUSC -0.857
non_ccRCC 0.254
PDAC -0.857
UCEC 0.579

PTM-Disease Association:

source: PTMD
Residue Position State Disease Class PMID
S 51 U Triple-negative breast cancer Phosphorylation 37834012
S 51 U Lung adenocarcinoma Phosphorylation 36226539

State Note: Based on the distinct PTM states in diseases, PTMD classified all disease-associated PTMs into six classes, including whether the up-regulation (U) or down-regulation (D) of PTM levels, the absence (A) or presence (P) of PTMs, and the creation (C) or disruption (N) of PTM sites are associated with diseases.

PTM-Drug Perturbation Response:

source: DecryptM

No data.

Function score:

source: funscoR

No data.

Cross Links: